Randomized Phase 2 Trial of ACP-196 and Pembrolizumab Immunotherapy Dual Checkpoint Inhibition in Platinum Resistant Metastatic Urothelial Carcinoma (RAPID CHECK Study)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 13 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Acalabrutinib (Primary) ; Pembrolizumab (Primary)
Indications Bladder cancer; Carcinoma; Ureteral neoplasms; Urogenital cancer
Focus Therapeutic Use
Acronyms KEYNOTE143; RAPID CHECK
Sponsors Acerta Pharma

05 Aug 2020 Results published in the Cancer
16 Feb 2019 Results evaluating flow analysis of peripheral blood mononuclear cells in cisplatin resistant metastatic urothelial cancer patients treated with pembrolizumab with or without acalabrutinib presented at the 2019 Genitourinary Cancers Symposium
05 Jun 2018 Status changed from active, no longer recruiting to completed, according to results presented at the 54th Annual Meeting of the American Society of Clinical Oncology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com